Biocept - BIOC Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month price objectives for Biocept's shares. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 624.0% from the stock's current price.
View analysts price targets for BIOC or view top-rated stocks among Wall Street analysts.

Biocept's stock was trading at $0.53 on January 1st, 2023. Since then, BIOC stock has increased by 4.2% and is now trading at $0.5525.
View the best growth stocks for 2023 here.

Biocept saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 143,500 shares, an increase of 93.7% from the December 31st total of 74,100 shares. Based on an average daily volume of 131,600 shares, the days-to-cover ratio is presently 1.1 days.
View Biocept's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 5th 2023.
View our BIOC earnings forecast.

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings data on Thursday, November, 10th. The medical research company reported ($0.31) EPS for the quarter. The medical research company earned $10.61 million during the quarter. Biocept had a negative net margin of 32.99% and a negative trailing twelve-month return on equity of 49.18%.

Biocept's stock reverse split on the morning of Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOC stock can currently be purchased for approximately $0.55.

Biocept (NASDAQ:BIOC) has a market capitalization of $9.43 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

The company employs 104 workers across the globe.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.